Literature DB >> 30119082

Bevacizumab in Cervical Cancer: 5 Years After.

Krista S Pfaendler1, Marisa C Liu1, Krishnansu S Tewari1.   

Abstract

Over the past 5 years, addition of bevacizumab to combination chemotherapy for advanced, recurrent, and persistent cervical cancer has offered prolonged overall and progression-free survival. Since the original press release announcing the survival benefits of this antiangiogenesis therapy, there has been further study of bevacizumab related to quality of life, combination with other agents, use of imaging to evaluate likelihood of response, and development of biosimilars. This review summarizes publications related to bevacizumab use in advanced, recurrent, and persistent cervical cancer over the past 5 years since initial proof of concept of antiangiogenesis therapy and the initial dissemination of information regarding survival benefits of bevacizumab.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30119082     DOI： 10.1097/PPO.0000000000000324

Source DB:  PubMed          Journal:  Cancer J        ISSN： 1528-9117            Impact factor:   3.360


  8 in total

Review 1.  Evidence-Based Treatment Paradigms for Management of Invasive Cervical Carcinoma.

Authors:  Krishnansu S Tewari; Bradley J Monk
Journal:  J Clin Oncol       Date:  2019-08-12       Impact factor: 44.544

Review 2.  Novel Therapeutics for Recurrent Cervical Cancer: Moving Towards Personalized Therapy.

Authors:  Alexander C Cohen; Brandon M Roane; Charles A Leath
Journal:  Drugs       Date:  2020-02       Impact factor: 9.546

3.  Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.

Authors:  Yunhai Chuai; Ivana Rizzuto; Xia Zhang; Ying Li; Guanghai Dai; Sophie J Otter; Rasiah Bharathan; Alexandra Stewart; Aiming Wang
Journal:  Cochrane Database Syst Rev       Date:  2021-03-04

4.  Low GAS5 expression may predict poor survival and cisplatin resistance in cervical cancer.

Authors:  Xingyu Fang; Guanglei Zhong; Yuhan Wang; Zhongqiu Lin; Rongchun Lin; Tingting Yao
Journal:  Cell Death Dis       Date:  2020-07-13       Impact factor: 8.469

Review 5.  Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.

Authors:  Stephen P Hack; Andrew X Zhu; Yulei Wang
Journal:  Front Immunol       Date:  2020-11-05       Impact factor: 7.561

6.  Engineered Exosomes-Mediated Transfer of hsa-miR-320a Overcomes Chemoresistance in Cervical Cancer Cells via Targeting MCL1.

Authors:  Jinling Zhou; Yuanhe Wang; Lizhu Zhang; Qin Chen; Xiaojun Zhu; Peiyue Jiang; Nan Jiang; Wei Zhao; Baohua Li
Journal:  Front Pharmacol       Date:  2022-04-04       Impact factor: 5.988

7.  Antiangiogenic Drug-Induced Proteinuria as a Prognostic Factor in Metastatic Colorectal Cancer.

Authors:  Diana Cornelia Moisuc; Mihai Vasile Marinca; Bogdan Gafton; Teodora Alexa-Stratulat; Mariana Pavel-Tanasa; Petru Cianga
Journal:  Curr Oncol       Date:  2022-05-31       Impact factor: 3.109

8.  Intensity-modulated radiation therapy (IMRT)-based concurrent chemoradiotherapy (CCRT) with Endostar in patients with pelvic locoregional recurrence of cervical cancer: Results from a hospital in the Qinghai-Tibet Plateau.

Authors:  Kuan Zhang; Huiping Wang; Zhenqing Wang; Fuqing Li; Ying Cui; Shengchun Ma; Rui Chen; Yuhui Wang; Shul Guo; Ying Wei
Journal:  Medicine (Baltimore)       Date:  2020-12-04       Impact factor: 1.817
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.